Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Part of paid clinical trials in Stony Brook, New York.

Sponsor
Alison Stopeck
Study ID
NCT04088032
Phase
EARLY_PHASE1
Status
Withdrawn

Conditions

  • Breast Cancer Female
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Locally Advanced Breast Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to test the efficacy, safety and tolerability of a combination of immunotherapy and anticancer drugs presurgery in patients with hormone-receptor positive breast cancer.

Key Dates

Start date
Oct 1, 2019
Status verified
Jul 2020
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Active
    Experimental treatment

Primary Outcome Measure

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: Through study completion, up to 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stony Brook University Cancer CenterStony BrookNew York11794-

Find similar trials in Stony Brook, NY

By research site
Stony Brook University Cancer Center· Stony Brook, NY

Related Studies